A new Covid-19 subvariant named BA.3.2, commonly called ‘Cicada’, has been detected in several countries, including the United States. The variant is drawing global attention as health authorities continue to study its behavior and potential impact.

According to reports, the variant has already been identified in more than 20 countries. However, India has not seen any rise in cases linked to this subvariant so far. Officials are closely monitoring the situation.

What Is the Cicada Variant?

BA.3.2 belongs to the Omicron family of Covid-19 variants. What makes it different is the unusually high number of mutations.

Reports suggest that the variant carries around 70 to 75 mutations, many of them in the spike protein. This part of the virus helps it enter human cells. Because of these changes, the variant may spread more easily and could partially escape immunity.

However, experts stress that a higher number of mutations does not automatically mean the virus is more dangerous.

Global Spread Under Watch

The Cicada variant has been detected in the United States and is currently under observation there. It has also been reported in parts of Europe and Asia.

So far, there are no signs of large-scale outbreaks linked to this variant. Still, its presence across multiple regions has prompted global health agencies to keep a close watch.

Symptoms Similar to Omicron

The symptoms linked to BA.3.2 appear to be similar to earlier Omicron variants. Common signs include fever, fatigue, sore throat, cough, and a runny or blocked nose.

Some people have also reported headaches, body aches, and mild breathing discomfort. Importantly, there is no clear evidence that this variant causes more severe illness than previous strains.

Transmissibility and Immune Escape Concerns

The main concern around the Cicada variant is whether it spreads faster or can bypass immunity.

Early data suggests that it may be more transmissible and could show some level of immune escape. This means people who are vaccinated or previously infected might still catch the virus again.

However, protection against severe illness is expected to remain strong. Experts also note that data is still evolving and conclusions may change with more research.

Should India Be Concerned?

At present, experts say there is no immediate reason to worry in India.

Surveillance systems are actively tracking new variants, and no major spike linked to BA.3.2 has been reported. Vaccines are still expected to protect against serious disease.

Health authorities recommend continued genome sequencing, monitoring hospital trends, and taking booster doses if needed.

Why This Variant Stands Out

The main issue with BA.3.2 is not its severity but the uncertainty around it.

Like earlier variants, it may take time for scientists to fully understand its real-world impact. Governments are therefore taking a careful approach—staying alert without causing panic.

For now, the Cicada variant is something to watch, not fear. While its high mutation count and global presence require attention, there is no solid proof that it is more severe or poses a major threat to India.